ClinicalTrials.gg
RecruitingNCT05966961POLYNOVO-CHDUpdated Nov 18, 2026

Novosyn® CHD vs Polyglactin 910 Suture to Close Wounds After Emergency or Elective Laparotomy or Laparoscopic Surgery

An observational study in Surgical Site Infection, sponsored by Aesculap AG. Recruiting at 11 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Aesculap AG (part of B. Braun) · Observational

How we know

From the registry’s dates

  • Started Sep 2023; still recruiting 3 years 2 months later.
Updated Nov 18, 2026First sites in Malaysia, South Korea and ThailandStudy contact changed+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
2,998
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 20 studies in Surgical Wound Infection with a site in Italy — 3 open to participants now, 3 under way, none of them phase 3. Surgical Wound Infection · Italy.

Started
2023
the only one that year
Observational
7 of 20
2 open now
Registered
17th of 20
by date
Lead sponsor
1 of 20
Aesculap AG

Among the 20 studies in Surgical Wound Infection with a site in Italy, this one is the only one that started in 2023, is one of 7 observational ones, and was the 17th registered.

Surgical Wound Infection

747 studies on the registry are indexed under Surgical Wound Infection; 152 are open to participants now.

Browse Surgical Wound Infection studies →

Open to participants now

3 of the 20 studies in Surgical Wound Infection with a site in Italy are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 85 Surgical Wound Infection studies recruiting now, 62 (73%) set no upper age limit and 16 (19%) stop at 75 or younger; 12 take children under 18; 14 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Surgical Wound Infection with a site in Italy, or all of them as a file.
02

Study summary

The aim of the study is to elucidate, if the colonization of bacteria is lower on the Novosyn® CHD suture compared to uncoated Polyglactin 910 suture, which will be assessed by the incidence of surgical site infections (SSI: A1 and A2). The results of this registry will generate further clinical evidence for the use and the benefit of a Chlorhexidine coated suture used to close the wound after an emergency or elective laparoscopic or laparotomy surgery. The benefit for individual patients lies in the early diagnosis of complications and in the optimized postoperative controls of a clinical study.

03

Conditions studied

  • Surgical Site Infection

Keywords

  • Chlorhexidine coated suture
  • emergency laparoscopic surgery
  • emergency laparotomy surgery
  • elective laparoscopic surgery
  • elective laparotomy surgery
  • Novosyn®
  • Polyglactin 910
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Patients undergoing wound closure after emergency or elective laparoscopic or laparotomy surgery

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients undergoing an emergency or elective laparotomy or laparoscopic surgery.
  • Written
  • Age≥ 18 years
  • Not incapacitated patient

Exclusion criteria

Exclusion Criteria:

  • No exclusion criteria except patients with allergy or to chlorhexidine
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
2,998 participants (estimated)
Target follow-up
30 Days
Patient registry
Yes

Groups and cohorts

  • Novosyn®

    Sutures will be used to close the laparotomy or trocar incision in emergency or elective surgery. The suture material will be applied for fascia closure (and subcutaneous closure if applicable) in the context of daily clinical routine

    Device: Novosyn® in emergency or elective laparotomy or laparoscopic surgery

  • Polyglactin 910

    Sutures will be used to close the laparotomy or trocar incision in emergency or elective surgery. The suture material will be applied for fascia closure (and subcutaneous closure if applicable) in the context of daily clinical routine

    Device: Polyglactin 910 in emergency or elective laparotomy or laparoscopic surgery

Interventions

  • DeviceNovosyn® in emergency or elective laparotomy or laparoscopic surgery

    Fascia closure (and subcutaneous closure if applicable) after emergency or elective laparotomy or laparoscopic surgery.

  • DevicePolyglactin 910 in emergency or elective laparotomy or laparoscopic surgery

    Fascia closure (and subcutaneous closure if applicable) after emergency or elective laparotomy or laparoscopic surgery.

06

What researchers measure

Primary outcomes

  1. Frequency of surgical site infection (superficial (A1) and deep (A2)

    The aim of the study is to elucidate, if the colonization of bacteria is lower on the Novosyn® CHD suture compared to uncoated Polyglactin 910 suture, which will be assessed by the incidence of surgical site infections (SSI: A1 and A2).

    Time frame: until 30 days + 5 days after surgery.

Secondary outcomes

  1. Handling of the suture material

    Assessment of the handling of the suture material intraoperatively using a questionnaire including different dimensions (knot security, tensile strength, knot run down, tissue drag etc.) with 5 evaluations levels (excellent, very good, good, satisfied, poor).

    Time frame: intraoperatively

  2. Length of hospital stay

    Number of days the patient has to stay in hospital after emergency or elective laparotomy or laparoscopic surgery

    Time frame: until discharge (approximately 10 days after surgery)

  3. Time to return to work

    Number of days the patient needed to return to work after emergency or elective laparotomy or laparoscopic surgery

    Time frame: until 30 days + 5 days after surgery.

  4. Incidence of Surgical Site Infection (SSI)

    Incidence of Surgical Site Infection (SSI) (superficial (A1), deep (A2) and organ space (A3)) at the time of discharge

    Time frame: at discharge (approximately 10 days after surgery)

  5. Incidence of SSI (superficial (A1), deep (A2) and organ space (A3)) stratified by wound class

    Incidence of SSI (superficial (A1), deep (A2) and organ space (A3)) stratified by wound class (Class I clean, Class II clean/contaminated, Class III contaminated, Class IV dirty/infected)

    Time frame: until 30 days + 5 days after surgery

  6. Cumulative Rate of postoperative complications

    Number of postoperative complications of any kind for descriptive analysis

    Time frame: discharge (approximately 10 days after surgery) and 30 days+ 5 days after surgery.

  7. Cumulative Rate of reoperation

    Number of reoperation of any kind for descriptive analysis

    Time frame: at discharge (approximately 10 days after surgery) and 30 days + 5 days after surgery.

  8. Cumulative Rate of suture removal due to wound problems

    Rate of suture removal due to wound problems (infection, dehiscence, residual material requiring removal) for descriptive analysis

    Time frame: at discharge (approximately 10 days after surgery) and 30 days + 5 days after surgery.

  9. Cumulative Rate of Re-suturing

    Rate of Re-suturing of any kind for descriptive analysis

    Time frame: at discharge (approximately 10 days after surgery) and 30 days + 5 days after surgery.

  10. Hernia rate

    Number of Wound Hernia including umbilical hernia verified by ultra-sound examination

    Time frame: 30 days + 5 days postoperatively

07

Study locations

11 of 11 sites recruiting
  • Policlinico di Bari
    Bari, Apulia 70124, Italy
    Recruiting
    • Silvia Malerba, Dr. · Contact
    • Silvia Malerba, Dr. · Principal investigator
  • Pineta Grande Hospital
    Castel Volturno, Campania 81030, Italy
    Recruiting
    • Francesco Stanzione, Dr. · Contact
    • Francesco Stanzione, Dr. · Principal investigator
  • Ospedale di Lavagna ASL 4
    Lavagna, Liguria 16033, Italy
    Recruiting
    • Irene Leale, Dr. · Contact
    • Irene Leale, Dr. · Principal investigator
  • Fondazione Ospedale Evangelico Betania
    Naples, Napels 80147, Italy
    Recruiting
    • Sonja Chiappeta, Dr. · Contact
  • ASL TO5
    Chieri, Piedmont 10023, Italy
    Recruiting
    • Caneparo, Dr. · Contact
    • Silvia Caneparo, Dr. · Principal investigator
  • University of Malaya Medical Centre
    Kuala Lumpur, Kuala Lumpur 59100, Malaysia
    Recruiting
    • Wei Jin Wong, Dr. · Contact
    • Wei Jin Wong, Dr. · Principal investigator
  • Severance Hospital
    Seoul, Seoul 03722, South Korea
    Recruiting
    • Hyuk Hur, Dr. · Contact
    • Hyuk Hur, Dr. · Principal investigator
  • Hospital Clínico San Carlos
    Madrid, Madrid 28040, Spain
    Recruiting
    • Antonio José Torres Garcia, Dr. · Contact
    • Antonio José Torres Garcia, Dr. · Principal investigator
  • Hospital Universitario de Canarias
    Santa Cruz de Tenerife, Spain
    Recruiting
    • Javier River Castellano, Dr. · Contact
  • Hospital Universitario Virgen del Rocío
    Seville, Spain
    Recruiting
    • Javier Pardillo Ruiz, Dr. · Contact
  • Chulalongkorn University
    Bangkok, 10330, Thailand
    Recruiting
    • Surasith Chaithongwongwatthana, Dr. · Contact
    • Surasith Chaithongwongwatthana, Dr. · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2023 (actual). Primary completion is estimated for Aug 2028, 59 months after the start.

Of 68 observational studies under Surgical Wound Infection, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 53. This study's planned 59 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 19, 2023
First posted
Aug 1, 2023
StartActual
Sep 18, 2023
Primary completionEst.
Aug 2028
CompletionEst.
Dec 2028
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
9 sites added, 2 sites removed — first sites in Malaysia, South Korea and Thailand
Show 9 added (5 Italy, 1 Spain, 1 Malaysia, 1 South Korea, 1 Thailand)
  • Hospital Clínico San Carlos · Madrid, Spain
  • Policlinico di Bari · Bari, Italy
  • Pineta Grande Hospital · Castel Volturno, Italy
  • Ospedale di Lavagna ASL 4 · Lavagna, Italy
  • Fondazione Ospedale Evangelico Betania · Naples, Italy
  • ASL TO5 · Chieri, Italy
  • University of Malaya Medical Centre · Kuala Lumpur, Malaysia
  • Severance Hospital · Seoul, South Korea
  • Chulalongkorn University · Bangkok, Thailand
Show 2 removed
  • Hospital Clínico San Carlos · Madrid, Spain
  • Pineta Grande Hospital · Naples, Italy
across 2 updates, Nov 5, 2026 – Nov 18, 2026
Contact
Study contact changed: i•••@bbraun.com→s•••@aesculap.de. See the current contact
Nov 5, 2026
Show all 2 updates
  1. Nov 18, 2026
    8 sites added, 1 site removed — first sites in Malaysia, South Korea and Thailand
    Show 8 added (5 Italy, 1 Malaysia, 1 South Korea, 1 Thailand)
    • Policlinico di Bari · Bari, Italy
    • Pineta Grande Hospital · Castel Volturno, Italy
    • Ospedale di Lavagna ASL 4 · Lavagna, Italy
    • Fondazione Ospedale Evangelico Betania · Naples, Italy
    • ASL TO5 · Chieri, Italy
    • University of Malaya Medical Centre · Kuala Lumpur, Malaysia
    • Severance Hospital · Seoul, South Korea
    • Chulalongkorn University · Bangkok, Thailand
    Show 1 removed
    • Pineta Grande Hospital · Naples, Italy
  2. Nov 5, 2026
    1 site added, 1 site removed
    Show site
    • Hospital Clínico San Carlos · Madrid, Spain
    Show 1 removed
    • Hospital Clínico San Carlos · Madrid, Spain
    Contact Study contact changed: i•••@bbraun.com→s•••@aesculap.de. See the current contact
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05966961
Lead sponsor
Aesculap AG
Collaborators
B.Braun Surgical SA
Responsible party
Sponsor
First posted
Aug 1, 2023
Start date
Sep 18, 2023
Primary completion
Aug 2028 (estimated)
Completion
Dec 2028 (estimated)
Last update
Nov 18, 2026

Study contacts

Jaume Garcia Lopez
Contact
info@bbraun.com
+34935866200
Anna Ibañez Jimenez, Dr.
Contact
studies@aesculap.de
Antonio José Torres Garcia, Prof. Dr.
principal investigator · Hospital San Carlos, Madrid

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion